Addendum
Brentuximab vedotin (cutaneous T-cell lymphoma) - Addendum to Commission G18-01
Report documents
-
Addendum
Brentuximab vedotin (cutaneous T-cell lymphoma) - Addendum to Commission G18-01
Additional information
Federal Joint Committee (G-BA)
2018-07-05 A G-BA decision was published.
Project details
- Project no.
- G18-06
- Commission
- Commission awarded on 23.05.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
Connected Projects
-
Dossier assessment
Brentuximab vedotin (cutaneous T-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed